The Market Reports: Supportive Care in Oncology Epidemiology Forecast to 2026
Forecast the diagnosed incident and the five-year diagnosed prevalent cases of all cancer in the 7MM, GlobalData epidemiologists selected reputable international cancer databases and nationally representative, population-based studies that provided the di
(EMAILWIRE.COM, April 05, 2018 ) There were 933,412 diagnosed incident cases of all cancer receiving chemotherapy treatment in men and women, ages 18 years and older, in the 7MM. Combination therapy was more common, with 75.8% of cases receiving chemotherapy in conjunction with surgery, radiation, or both. The remaining cases, 24.2%, received chemotherapy alone. Of those receiving chemotherapy, anemia and nausea and vomiting were the most common conditions resulting from the treatment. In 2016, there were 809,204 cases of chemotherapy-induced anemia and 746,730 cases of chemotherapy-induced nausea and vomiting in the 7MM.
Report Source: https://www.themarketreports.com/report/epicast-report-supportive-care-in-oncology-epidemiology-forecast-to-2026
Scope
• The Supportive Care in Oncology EpiCast Report provides an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.
• The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Purchase this report at: https://www.themarketreports.com/report/buy-now/939287
Reasons To Buy
• Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.
• Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.
• Understand magnitude of chemotherapy induced conditions.
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/939287
Report Source: https://www.themarketreports.com/report/epicast-report-supportive-care-in-oncology-epidemiology-forecast-to-2026
Scope
• The Supportive Care in Oncology EpiCast Report provides an overview of the risk factors and global trends of supportive care in oncology in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• This report also includes a 10-year epidemiological forecast for the following segmentations in ages 18 years and older across the 7MM: diagnosed incident cases of all cancer; five-year diagnosed prevalent cases of all cancer; diagnosed incident cases of all cancer treated with chemotherapy; diagnosed incident cases all cancer treated with chemotherapy with chemotherapy induced condition (neutropenia, anemia, oral mucositis, nausea and vomiting, and cachexia); diagnosed incident cases of prostate cancer (men ages 35 years and older); diagnosed incident cases of breast cancer (women ages 20 years and older); diagnosed incident cases of lung cancer (men and women ages 20 years and older); diagnosed incident cases of prostate, breast, and lung cancer that metastasize to bone.
• The supportive care in oncology epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Purchase this report at: https://www.themarketreports.com/report/buy-now/939287
Reasons To Buy
• Develop business strategies by understanding the trends shaping and driving the global oncology and chemotherapy treatment market.
• Quantify patient populations in the global oncology and chemotherapy treatment market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chemotherapy induced conditions therapeutics in each of the markets covered.
• Understand magnitude of chemotherapy induced conditions.
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/939287
Contact Information:
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results